EGFR and leukemia: The era of precision medicine has promoted the development of many drugs that are specific for the highly active mutant forms of proteins, and has resulted in huge clinical benefits, as in the case of leukemia with Bcr-Abl translocations (treated with Imatinib); and lung cancers with EGFR mutations (gefitinib), amongst others [4, 46].